Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-3.25%||6.26||0.7%||$437.60m|
|GILD||Gilead Sciences, Inc.||-2.56%||65.90||1.0%||$415.54m|
|REGN||Regeneron Pharmaceuticals, Inc.||-1.76%||543.48||2.7%||$401.78m|
|XLRN||Acceleron Pharma, Inc.||0.04%||173.00||5.3%||$345.57m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.53%||180.80||1.9%||$258.21m|
|XENE||Xenon Pharmaceuticals, Inc.||-8.73%||30.72||0.4%||$162.62m|
|CRSP||CRISPR Therapeutics AG||-0.81%||96.21||0.6%||$151.63m|
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.